Defence Therapeutics has appointed Ryan Simms, PhD, as Chief Operating Officer and Head of Radiopharmaceutical Programs to enhance its leadership and accelerate its radiopharmaceutical drug conjugate programs. Simms brings over 20 years of experience in targeted radiopharmaceuticals, having held key roles at Fusion Pharmaceuticals and other biotech firms. His expertise will help Defence select lead candidates and advance them through preclinical stages while establishing manufacturing frameworks. This move, along with recent leadership changes and a new office in a major Canadian radiopharmaceutical hub, positions Defence for growth in precision oncology therapeutics.
Six Flags Entertainment Corporation announced its biggest Halloween event lineup for 2026, featuring 11 new haunted mazes inspired by popular horror franchises like Jason Universe™, Diablo®, Final Destination™, and The Blair Witch Project®. The event...
Halper Sadeh LLC is investigating whether officers and directors of Extreme Networks, Inc. breached their fiduciary duties to shareholders. Long-term shareholders may be entitled to seek reforms, financial incentives, or other relief. The firm offers...
Tertiary Minerals PLC has discovered a new shallow copper-mineralised zone at its Mushima North project in Zambia, located about 900 meters from the existing Discovery Zone. Preliminary pXRF results show promising copper grades, though lab assays are...
Arc Minerals announced a new diamond drilling campaign exceeding 6,000 metres at its Virgo copper project in Botswana, targeting areas near MMG's Khoemacau mining project. The drilling will focus on about 14 kilometres of the Kalahari Copper Belt, te...
Halper Sadeh LLC is investigating whether officers and directors of Perpetua Resources Corp. breached their fiduciary duties to shareholders. Long-term shareholders may seek reforms, financial awards, or other relief if misconduct is found. The firm ...
